Year Founded
2020
Ownership
Private
Employees
~100
Stage
Preclinical
Modalities
Molecular glue degraderProteolysis-targeting chimera (PROTAC)Small molecule

Neomorph General Information

Developing molecular glue degraders to target previously undruggable proteins. Has established multiple major pharma partnerships but no clinical candidates disclosed yet.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

No pipeline data available

For full access to Neomorph's pipeline data

Book a demo

Key Partnerships

AbbVie, Biogen, Novo Nordisk

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Neomorph Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Neomorph's complete valuation and funding history, request access »

Neomorph Investors

Deerfield Management Company
Investor Type: Venture Capital
Holding: Minority